In a prespecified per-protocol analysis of patients who received at least three doses ( two doses of Cy/GVAX plus one of CRS-207 or three of Cy/GVAX ) , OS was 9.7 versus 4.6 months ( arm A v B ; HR , 0.53 ; P = .02 ) .